Physician profile
Amanda Brown
NPI 1275913360
$2,497.49
in general payments reported to CMS, 2019-2025
23 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $216 · 2023: $556 · 2024: $563 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,175.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $429.70 | 2021-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $294.17 | 2023-2025 | Omnipod |
| Lilly USA, LLC | $250.36 | 2022-2025 | Mounjaro, Zepbound, Humulin |
| Corcept Therapeutics | $238.71 | 2024-2025 | Korlym |
| Amgen INC. | $200.14 | 2022-2025 | Evenity, Tepezza, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $192.41 | 2022-2025 | |
| Abbvie INC. | $143.72 | 2023-2025 | |
| Novo Nordisk INC | $132.48 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Forte Bio-Pharma LLC | $99.45 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Medtronic, INC. | $97.26 | 2024-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $65.90 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $54.93 | 2022-2025 | |
| Exact Sciences Corporation | $47.90 | 2023-2025 | Cologuard Collection Kit |
| Amryt Pharma Holdings LTD | $46.44 | 2021-2023 | Mycapssa |
| Horizon Therapeutics Plc | $40.63 | 2023 | Tepezza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.98 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $23.63 | 2025 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $23.47 | 2021 | |
| Axsome Therapeutics, INC. | $22.79 | 2024 | Auvelity |
| Ascendis Pharma Endocrinology INC | $20.37 | 2025 | Yorvipath |
| Novartis Pharmaceuticals Corporation | $17.46 | 2022 | |
| Currax Pharmaceuticals LLC | $13.76 | 2024 | Contrave |
| Abbott Laboratories | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.